You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain
SBC: 4E THERAPEUTICS, INC. Topic: 104Abstract The goal of this project is to develop an optimized MNK inhibitor for neuropathic pain treatment. MNK is a kinase that phosphorylates eIF4E to control the translation of a distinct subset of mRNAs. Our focus on this target for neuropathic pain is grounded in evidence that MNK-eIF4E signaling is activated in nociceptors upon exposure to pain promoting cytokines and growth factors as well a ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Human Neural Cell Exosomes as a Therapeutic Treatment for Stroke
SBC: ARUNA BIO, INC. Topic: NINDSProject Summary Cytoprotective and restorative treatments for acute ischemic stroke (AIS) is a major unmet medical need. The current standard of care for stroke patients is centered on recanalization efforts to restore cerebral perfusion through the administration of tissue plasminogen activator (tPA) or mechanical thrombectomy. However, despite a recent extension of recanalization treatment windo ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
SBC: SAVARA INC. Topic: NHLBIDESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prevalence of almost in CF patients in the US This is concerning as MRSA positivity is associated with a faster decline of lung function and a years shorter median life expectancy compared to CF p ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
SBC: RIDGELINE THERAPEUTICS LLC Topic: NIAMuscle-aging is defined by progressive declines in mass and strength that poses a high risk for falls, fatal injury, and trauma-related fractures among older Americans (age 60+). Each year, rt30% of older adults suffer a fall, resulting in ~2.8 million traumatic fractures that significantly reduce mobility, independence, overall health, and quality of life for the elderly. Among fall-related injur ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Improved AD/ADRD Assessment Sensitivities Using a Novel In-Situ Sensor System
SBC: Birkeland Current LLC Topic: NIAProject Summary/AbstractAccurate assessment of daily functions for individuals at risk for and with AD/ADRD, is fundamental to detection, diagnosis, and characterization of its progression and prescribed treatments. Current assessment techniques typically rely on non- continuous, discreet observations provided from a third party and covering single or limited performance domains. With significantl ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage
SBC: NEUROP, INC. Topic: 102Abstract Subarachnoid hemorrhageSAHremains a serious source of neurological morbiditywith approximatelycases reported in the US each yearDespite advances in treating the initial and subsequent bleedspost surgical clipping of the aneurysm is associated with a significant risk of delayed cerebral ischemiaDCIThese events typically occur within the firstdays after aneurysmal rupture and DCI remains th ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Finalizing and Testing an Online Therapist Training and Assistance Program to Facilitate Implementation of Comprehensive Behavioral Intervention for Tic Disorders (CBIT-Trainer)
SBC: PSYC Tech, Ltd. Topic: 104Abstract (Project 2R44MH111450-03A1) Tic disorders (TDs) are a class of neurodevelopmental disorders characterized by involuntary motor and vocal tics1 that affect 1%-3% of the population2 and cause substantial distress, interference and disability.3-9 Comprehensive Behavioral Intervention for Tics (CBIT) is an empirically-validated collection of behavioral tic management techniques that is now in ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Increasing size of Phase 2b clinical trial to 60 patients
SBC: PAIN THERAPEUTICS, INC. Topic: NIAProject Summary/Abstract PTI-125 is a novel small molecule Alzheimer’s disease (AD) therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42’s tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42’s aberrant activati ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Additional costs related to formulation, chronic tox and general development of PTI-125
SBC: PAIN THERAPEUTICS, INC. Topic: NIAProject Summary Abstract PTIis a novel small molecule AD therapeutic candidate with a novel target and mechanism of actionPTIbinds and reverses an altered conformation of the scaffolding protein filamin AFLNAto prevent Aandapos s tight binding to and toxic signaling via thenicotinic acetylcholine receptornAChRas well as Aandapos s aberrant activation of toll like receptorTLRHenceby restoring FLNAa ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme
SBC: NEUROP, INC. Topic: 102DESCRIPTION provided by applicant Cerebral ischemia is a major cause of death and long term disability with high accompanying social and medical costs Approximately Americans suffer a stroke each year at an estimated annual cost of $ B American Heart Association Heart Disease and Stroke Statistics Update Substantial preclinical data support the use of NMDA receptor antago ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health